Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Sell
50
BG Quote, Financials, Valuation and Earnings
Last price:
$80.32
Seasonality move
:
2.65%
Day range:
$79.76 - $81.68
52-week range:
$67.40 - $114.92
Dividend yield:
3.34%
P/E ratio:
10.35x
P/S ratio:
0.22x
P/B ratio:
1.04x
Volume:
1.2M
Avg. volume:
1.8M
1-year change:
-21.77%
Market cap:
$11B
Revenue:
$53.1B
EPS (TTM):
$7.88
Analysts' Opinion
-
Consensus RatingBunge Global SA has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $87.43, Bunge Global SA has an estimated upside of 7.23% from its current price of $81.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $74.00 representing 100% downside risk from its current price of $81.54.
Fair Value
-
According to the consensus of 9 analysts, Bunge Global SA has 7.23% upside to fair value with a price target of $87.43 per share.
BG vs. S&P 500
-
Over the past 5 trading days, Bunge Global SA has overperformed the S&P 500 by 0.14% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bunge Global SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bunge Global SA revenues have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Bunge Global SA reported revenues of $11.6B.
Earnings Growth
-
Bunge Global SA earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bunge Global SA reported earnings per share of $1.48.
Enterprise value:
14.8B
EV / Invested capital:
0.81x
Price / LTM sales:
0.22x
EV / EBIT:
7.77x
EV / Revenue:
0.29x
PEG ratio (5yr expected):
0.38x
EV / Free cash flow:
-17.86x
Price / Operating cash flow:
20.60x
Enterprise value / EBITDA:
6.22x
Gross Profit (TTM):
$3.1B
Return On Assets:
4.31%
Net Income Margin (TTM):
2.13%
Return On Equity:
9.73%
Return On Invested Capital:
6.4%
Operating Margin:
1.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $66.7B | $57.6B | $51.3B | $13.4B | $11.6B | |
| Gross Profit | $3.7B | $4.5B | $3.1B | $876M | $597M | |
| Operating Income | $2.2B | $2.7B | $1.4B | $437M | $217M | |
| EBITDA | $2.9B | $3.6B | $2.4B | $589M | $508M | |
| Diluted EPS | $10.19 | $12.40 | $7.88 | $1.68 | $1.48 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.3B | $20.9B | $19B | $16.7B | $17.4B | |
| Total Assets | $24.5B | $28.7B | $27.1B | $25.8B | $26.7B | |
| Current Liabilities | $11.3B | $13.9B | $10.4B | $8.4B | $8.5B | |
| Total Liabilities | $17.3B | $19.6B | $16.4B | $14.3B | $15.1B | |
| Total Equity | $7.3B | $9.1B | $10.7B | $11.5B | $11.6B | |
| Total Debt | $7.1B | $6.5B | $5.7B | $5.1B | $6.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2B | $3.4B | $621M | $994M | -$285M | |
| Cash From Investing | $5.1B | -$1.5B | -$998M | -$396M | -$280M | |
| Cash From Financing | -$576M | -$2B | $659M | -$259M | $490M | |
| Free Cash Flow | -$2.6B | $2.2B | -$829M | $758M | -$595M | |
BG
Sector
Market Cap
$11B
$257.5M
Price % of 52-Week High
70.95%
75.86%
Dividend Yield
3.34%
0%
Shareholder Yield
6.8%
2.91%
1-Year Price Total Return
-21.77%
-13.43%
Beta (5-Year)
0.683
0.395
Dividend yield:
3.34%
Annualized payout:
$2.70
Payout ratio:
34.19%
Growth streak:
4 years
Technicals
8-day SMA
Buy
Level
$79.51
200-day SMA
Sell
Level
$84.93
Bollinger Bands (100)
Buy
Level
72.69 - 79.65
Chaikin Money Flow
Buy
Level
167M
20-day SMA
Buy
Level
$79.49
Relative Strength Index (RSI14)
Buy
Level
58.64
ADX Line
Buy
Level
13.45
Williams %R
Neutral
Level
-26.3514
50-day SMA
Buy
Level
$76.75
MACD (12, 26)
Buy
Level
1.13
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
229M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.978)
Buy
CA Score
(Annual)
Level (0.3242)
Buy
Beneish M-Score
(Annual)
Level (-2.8463)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.5977)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
Stock Forecast FAQ
In the current month, BG has received 4 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BG average analyst price target in the past 3 months is $87.43.
-
Where Will Bunge Global SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bunge Global SA share price will rise to $87.43 per share over the next 12 months.
-
What Do Analysts Say About Bunge Global SA?
Analysts are divided on their view about Bunge Global SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bunge Global SA is a Sell and believe this share price will drop from its current level to $74.00.
-
What Is Bunge Global SA's Price Target?
The price target for Bunge Global SA over the next 1-year time period is forecast to be $87.43 according to 9 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bunge Global SA is a Hold. 5 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BG?
You can purchase shares of Bunge Global SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bunge Global SA shares.
-
What Is The Bunge Global SA Share Price Today?
Bunge Global SA was last trading at $80.32 per share. This represents the most recent stock quote for Bunge Global SA. Yesterday, Bunge Global SA closed at $81.54 per share.
-
How To Buy Bunge Global SA Stock Online?
In order to purchase Bunge Global SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
81
SMLR alert for May 19
Semler Scientific [SMLR] is up 5.85% over the past day.
Sell
25
GLOB alert for May 19
Globant SA [GLOB] is up 4.02% over the past day.
Buy
94
HIMS alert for May 19
Hims & Hers Health [HIMS] is down 3.57% over the past day.
